Drug-Induced Mitochondrial Dysfunction - Rilegato

Rilegato

ISBN 10: 0470111313 ISBN 13: 9780470111314

Casa editrice: Wiley-Interscience, 2008

Riassunto

This is the definitive, one-stop resource on preclinical drug evaluation for potential mitochondrial toxicity, addressing the issue upfront in the drug development process. It discusses mitochondrial impairment to organs, skeletal muscle, and nervous systems and details methodologies used to assess mitochondria function. It covers both in vitro and in vivo methods for analysis and includes the latest models. This is the authoritative reference on drug-induced mitochondrial dysfunction for safety assessment professionals in the pharmaceutical industry and for pharmacologists and toxicologists in both drug and environmental health sciences.

Su questo libro

Informazioni sull'autore

James A. Dykens, PhD, is an Associate Research Fellow in Pfizer's Drug Safety Research and Development Department. Currently in Sandwich, England, he previously worked in a similar role with Pfizer in La Jolla, California. Prior to his work with Pfizer, Dr. Dykens was the senior director of technology development for MIGENIX Inc., a senior scientist and the director of business development at MitoKor, Inc., and a senior principal scientist at Parke-Davis Pharmaceutical Research. Dr. Dykens has published extensively on drug-induced mitochondrial dysfunction, on the role of mitochondrial free radical production in the etiology of neurodegenerative diseases, and on the physiological ecology of marine symbioses.

Yvonne Will, PhD, works in Pfizer's Exploratory Safety Differentiation Group in Groton, Connecticut. Prior to this position, she led Pfizer's Investigative Biochemical Toxicity Group within the Drug Safety Research and Development Department in La Jolla. Before joining Pfizer, Dr. Will worked on mitochondrial proteomics and physiology at MitoKor, Inc. Dr. Will has authored a host of articles and book chapters. She is a member of the Society of Toxicology and a frequent speaker for groups like ACT and World Pharmaceutical Congress.

Dalla quarta di copertina

Preclinical screening for drug-induced mitochondrial dysfunction can predict toxicity and revolutionize drug development

All too often, despite adherence to regulatory guidelines, a new drug reaches the market and its toxicity is not discovered until many patients have been exposed. In many cases, this unpredicted toxicity is due to the drug's adverse effects on mitochondrial function or replication. This reference presents technological developments that facilitate preclinical drug evaluation for potential mitochondrial toxicity, addressing the issue early in the drug development process. With chapters contributed by leading specialists in their areas, Drug-Induced Mitochondrial Dysfunction:

• Explains basic concepts so that non-specialists can understand mitochondrial function

• Discusses mitochondrial etiology of organ toxicity, covering the liver, heart, and kidney, as well as the skeletal muscle, nervous system, and lipoatrophy

• Details methodologies and techniques used to assess mitochondria function so researchers can address drug-induced mitochondrial impairment in their own labs

• Includes new models that detect drug-induced mitochondrial impairment in short-duration studies typical of preclinical drug evaluations

• Features both in vitro and in vivo methods for analysis, including practical screening approaches for drug discovery and development

This is the authoritative reference on drug-induced mitochondrial dysfunction for safety assessment professionals in the pharmaceutical industry, including bench scientists and managers, and for pharmacologists and toxicologists in both drug and environmental health sciences.

Dal risvolto di copertina interno

Preclinical screening for drug-induced mitochondrial dysfunction can predict toxicity and revolutionize drug development
 
All too often, despite adherence to regulatory guidelines, a new drug reaches the market and its toxicity is not discovered until many patients have been exposed. In many cases, this unpredicted toxicity is due to the drug's adverse effects on mitochondrial function or replication. This reference presents technological developments that facilitate preclinical drug evaluation for potential mitochondrial toxicity, addressing the issue early in the drug development process. With chapters contributed by leading specialists in their areas, Drug-Induced Mitochondrial Dysfunction:
* Explains basic concepts so that non-specialists can understand mitochondrial function
* Discusses mitochondrial etiology of organ toxicity, covering the liver, heart, and kidney, as well as the skeletal muscle, nervous system, and lipoatrophy
* Details methodologies and techniques used to assess mitochondria function so researchers can address drug-induced mitochondrial impairment in their own labs
* Includes new models that detect drug-induced mitochondrial impairment in short-duration studies typical of preclinical drug evaluations
* Features both in vitro and in vivo methods for analysis, including practical screening approaches for drug discovery and development
 
This is the authoritative reference on drug-induced mitochondrial dysfunction for safety assessment professionals in the pharmaceutical industry, including bench scientists and managers, and for pharmacologists and toxicologists in both drug and environmental health sciences.

Dettagli dell'edizione

• Editore: Wiley-Interscience
• Data di pubblicazione: 2008
• Lingua: Inglese
• ISBN 10: 0470111313
• ISBN 13: 9780470111314
• Rilegatura: Copertina rigida
• Numero edizione: 1
• Numero di pagine: 616
• Redattore: Dykens James A., Will Yvonne
• Contatto del produttore: Easy Access System Europe Oü, 16879218; gpsr.requests@easproject.com; ; Mustamäe tee 50, 10621, Tallinn, Estonia; Tallinn; 10621; Estonia